ADAG Quote, Financials, Valuation and Earnings

Viva Biotech Holdings has a net margin of -- compared to Adagene, Inc.'s net margin of --. Adagene, Inc.'s return on equity of -56.44% beat Viva Biotech Holdings's return on equity of -1.8%.

Adagene, Inc. has a consensus price target of $8.00, signalling upside risk potential of 170.27%. On the other hand Viva Biotech Holdings has an analysts' consensus of -- which suggests that it could fall by --. Given that Adagene, Inc. has higher upside potential than Viva Biotech Holdings, analysts believe Adagene, Inc. is more attractive than Viva Biotech Holdings.

Adagene, Inc. has a beta of 0.706, which suggesting that the stock is 29.403% less volatile than S&P 500. In comparison Viva Biotech Holdings has a beta of 0.576, suggesting its less volatile than the S&P 500 by 42.44%.

Adagene, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viva Biotech Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adagene, Inc. pays -- of its earnings as a dividend. Viva Biotech Holdings pays out -- of its earnings as a dividend.

Adagene, Inc. quarterly revenues are --, which are smaller than Viva Biotech Holdings quarterly revenues of --. Adagene, Inc.'s net income of -- is lower than Viva Biotech Holdings's net income of --. Notably, Adagene, Inc.'s price-to-earnings ratio is -- while Viva Biotech Holdings's PE ratio is 19.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adagene, Inc. is 1,332.16x versus 3.15x for Viva Biotech Holdings. Usually stocks with elevated PS ratios are considered overvalued.

WuXi Biologics (Cayman), Inc. has a net margin of -- compared to Adagene, Inc.'s net margin of --. Adagene, Inc.'s return on equity of -56.44% beat WuXi Biologics (Cayman), Inc.'s return on equity of 7.53%.

Adagene, Inc. has a consensus price target of $8.00, signalling upside risk potential of 170.27%. On the other hand WuXi Biologics (Cayman), Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Adagene, Inc. has higher upside potential than WuXi Biologics (Cayman), Inc., analysts believe Adagene, Inc. is more attractive than WuXi Biologics (Cayman), Inc..

Adagene, Inc. has a beta of 0.706, which suggesting that the stock is 29.403% less volatile than S&P 500. In comparison WuXi Biologics (Cayman), Inc. has a beta of -0.063, suggesting its less volatile than the S&P 500 by 106.255%.

Adagene, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. WuXi Biologics (Cayman), Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adagene, Inc. pays -- of its earnings as a dividend. WuXi Biologics (Cayman), Inc. pays out -- of its earnings as a dividend.

Adagene, Inc. quarterly revenues are --, which are smaller than WuXi Biologics (Cayman), Inc. quarterly revenues of --. Adagene, Inc.'s net income of -- is lower than WuXi Biologics (Cayman), Inc.'s net income of --. Notably, Adagene, Inc.'s price-to-earnings ratio is -- while WuXi Biologics (Cayman), Inc.'s PE ratio is 29.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adagene, Inc. is 1,332.16x versus 7.71x for WuXi Biologics (Cayman), Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Zai Lab Ltd. has a net margin of -- compared to Adagene, Inc.'s net margin of -39.51%. Adagene, Inc.'s return on equity of -56.44% beat Zai Lab Ltd.'s return on equity of -22.45%.

Adagene, Inc. has a consensus price target of $8.00, signalling upside risk potential of 170.27%. On the other hand Zai Lab Ltd. has an analysts' consensus of $41.44 which suggests that it could grow by 115.63%. Given that Adagene, Inc. has higher upside potential than Zai Lab Ltd., analysts believe Adagene, Inc. is more attractive than Zai Lab Ltd..

Adagene, Inc. has a beta of 0.706, which suggesting that the stock is 29.403% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.854, suggesting its less volatile than the S&P 500 by 14.611%.

Adagene, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adagene, Inc. pays -- of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend.

Adagene, Inc. quarterly revenues are --, which are smaller than Zai Lab Ltd. quarterly revenues of $128.2M. Adagene, Inc.'s net income of -- is lower than Zai Lab Ltd.'s net income of -$50.6M. Notably, Adagene, Inc.'s price-to-earnings ratio is -- while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adagene, Inc. is 1,332.16x versus 4.56x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.